Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaronsmead 2vt Regulatory News (BMD)

Share Price Information for Baronsmead 2vt (BMD)

Share Price is delayed by 15 minutes
Get Live Data
45.00    0.00 (0.00%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £195.03m
BMD Live PriceLast checked at - London Stock Exchange

Intraday Baronsmead 2vt Share Chart

Issue of Equity

30 Nov 2016 14:45

RNS Number : 5897Q
Baronsmead Second Venture Trust PLC
30 November 2016
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR south africa OR any jurisdiction in which the same could be unlawful. the information contained herein does not constitute an offer of securities for sale in any jurisdiction, including in the united states, CANADA, australia, japan OR south africa.

BARONSMEAD SECOND VENTURE TRUST PLC

30 NOVEMBER 2016

ISSUE OF NEW SHARES IN CONNECTION WITH THE RECONSTRUCTION AND WINDING UP OF BARONSMEAD VCT 5 PLC

The Board of Baronsmead Second Venture Trust plc (the "Company") refers to the circular and prospectus published by the Company on 17 October 2016 in connection with the participation of the Company in the proposed scheme for the reconstruction and winding up of Baronsmead VCT 5 plc ("BVCT5"). 

The Board is pleased to announce that, following the passing of the resolution at the general meeting of BVCT5 earlier today, the Company will acquire approximately £43 million of assets of BVCT5 in consideration for the issue of New Shares to BVCT5 Shareholders. The Company already holds investments in all of the companies that make up the BVCT5 portfolio of assets.

The number of New Shares to be issued to BVCT5 Shareholders under the BVCT5 Scheme will be based on the adjusted Net Asset Value of an Ordinary Share (the "FAV per Ordinary Share") and the adjusted Net Asset Value of a BVCT5 Share (the "FAV per BVCT5 Share"). The FAV per Ordinary Share and the FAV per BVCT5 Share were calculated as at close of business on 28 November 2016. The FAV per Ordinary Share was 90.67 pence and the FAV per BVCT5 Share was 76.05 pence. BVCT5 Shareholders will receive approximately 0.838803 New Shares for every BVCT5 Share, accordingly the Company will issue 47,077,911 New Shares under the Scheme.

Applications have been made for the New Shares to be issued pursuant to the Scheme to be admitted to the Official List (with a Premium Listing) and to the London Stock Exchange for the New Shares to be admitted to trading on the Main Market. It is expected that Admission will occur and dealings will commence in the New Shares to be issued pursuant to the Scheme at 8.00 a.m. on 2 December 2016.

Each Ordinary Share has one voting right. Following the issue of New Shares pursuant to the Scheme, the Company will have 209,037,921 Ordinary Shares in issue (of which 9,089,214 Ordinary Shares are held in treasury). The total number of voting rights in the Company will therefore be 199,948,707 and this figure may be used by Ordinary Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure Guidance and Transparency Rules. 

Changes to the Board

Following approval of the Proposals, John Davies has joined the board of the Company as a non-executive director, with immediate effect. Save for as disclosed in the Prospectus, there are no other details to be disclosed pursuant to Listing Rule 9.6.13 in relation to this Board appointment. A copy of the Prospectus is available for inspection at the National Storage Mechanism, which is located at http://www.morningstar.co.uk/uk/NSM.

 

Definitions

Terms defined in the circular published by the Company dated 17 October 2016 have the same meanings in this announcement unless the context requires otherwise.

Further information

For further information please contact.

Michael Probin - VCT investor relationsLivingbridge VC LLP020 7506 5796

Notes

This announcement is for information purposes only and does not purport to be full or complete and any decision regarding the Proposals should be made only on the basis of the Circular and the Prospectus. 

This announcement does not constitute or form part of any offer to issue or sell, or any solicitation of any offer to subscribe or purchase, any investment in any jurisdiction, nor shall it (or the fact of its distribution) form the basis of, or be relied on in connection with, any contract therefor. 

The issue and the distribution of this announcement, the Circular and/or the Prospectus in certain jurisdictions may be restricted by law and persons into whose possession any document or other information referred to this announcement, the Circular and/or the Prospectus comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEZBLFXQFFZFBX
Date   Source Headline
4th Jun 20263:15 pmRNSNet Asset Value(s)
3rd Jun 202610:15 amRNSNewsletter for the period June 2025 to March 2026
1st Jun 202611:26 amRNSTotal Voting Rights
18th May 20263:45 pmRNSAdmission of Further Securities to Trading
14th May 20262:15 pmRNSAllotment of Shares and Closure of Offer
11th May 20267:00 amRNSNet Asset Value(s)
5th May 20263:15 pmRNSNet Asset Value(s)
1st May 202611:42 amRNSTotal Voting Rights
8th Apr 202610:15 amRNSAdmission of Further Securities to Trading
1st Apr 202611:48 amRNSTotal Voting Rights
31st Mar 20265:37 pmRNSTransaction in Own Shares
30th Mar 20261:50 pmRNSNet Asset Value(s)
24th Mar 20262:25 pmRNSReplacement - Extension to Application Deadline
24th Mar 202612:20 pmRNSApplication Deadline Extension - Fourth Allotment
20th Mar 20267:00 amRNSResult of AGM
11th Mar 20262:00 pmRNSOver-Allotment Facility and Offer Update
5th Mar 20263:30 pmRNSNet Asset Value(s)
2nd Mar 202611:38 amRNSTotal Voting Rights
26th Feb 202612:15 pmRNSAdmission of Further Securities to Trading
20th Feb 202611:02 amRNSDirector/PDMR Shareholding
19th Feb 20264:30 pmRNSAllotment of Shares and Total Voting Rights
17th Feb 20264:05 pmRNSTransaction in Own Shares
6th Feb 202612:06 pmRNSOffer Update:Close of Early Subscription Incentive
5th Feb 20264:15 pmRNSNet Asset Value(s)
2nd Feb 20264:45 pmRNSNet Asset Value(s)
2nd Feb 202610:39 amRNSTotal Voting Rights
29th Jan 20263:35 pmRNSAdmission of Further Securities to Trading
22nd Jan 20263:40 pmRNSAllotment of Shares and Total Voting Rights
12th Jan 202611:35 amRNSPublication of a Supplementary Prospectus
23rd Dec 20257:00 amRNSAnnual Financial Report
23rd Dec 20257:00 amRNSAnnual Financial Report
4th Dec 20253:45 pmRNSNet Asset Value(s)
1st Dec 202510:44 amRNSTotal Voting Rights
20th Nov 20251:22 pmRNSDirector/PDMR Shareholding
20th Nov 202512:00 pmRNSAllotment of Shares and Total Voting Rights
6th Nov 20254:00 pmRNSNet Asset Value(s)
29th Oct 20259:45 amRNSNet Asset Value(s)
13th Oct 20252:00 pmRNSPublication of a Prospectus/Offer for Subscription
1st Oct 20257:00 amRNSTotal Voting Rights
29th Sep 20255:56 pmRNSTransaction in Own Shares
24th Sep 20258:46 amRNSUpdate on Offer for Subscription
23rd Sep 20252:49 pmRNSQuarterly Factsheet June 2025 & Newsletter H2 2025
11th Sep 20256:06 pmRNSTransaction in Own Shares
11th Sep 20255:09 pmRNSDirector/PDMR Shareholding
4th Sep 20253:15 pmRNSNet Asset Value(s)
4th Sep 20258:15 amRNSIntention to Fundraise
6th Aug 20254:15 pmRNSNet Asset Value(s)
31st Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 202510:00 amRNSNet Asset Value(s)
1st Jul 20255:13 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.